{"metadata":{"topics":["ADME","Abbreviated New Drug Application","Absorption (pharmacology)","Accountability","Accountant","Accounting","Act of God","Active ingredient","Active metabolite","Administrative law","Adverse effect","Adverse event","Advertising","Aid","American Arbitration Association","Anti-competitive behaviour","Appeal","Application programming interface","Applied ethics","Arbitration","Arm's length principle","Article Four of the United States Constitution","Article One of the United States Constitution","Article Three of the United States Constitution","Artificial objects","Asset","Assignment (law)","Attention","Attorney's fee","Audit","Average","Bank","Bankruptcy","Barter","Biochemistry","Bioequivalence","Biology","Biotechnology","Blister pack","Breach of contract","Business","Business economics","Business law","Business process","By-law","Cargo","Cash","Certified Public Accountant","Chargeback","Chemical compound","Chemical formula","Chemical substance","Chemistry","Choice of law","Civil law (common law)","Civil law (legal system)","Clinical medicine","Clinical pharmacology","Clinical research","Clinical trial","Co-marketing","Cognition","Cognitive science","Common carrier","Common law","Communication","Companies","Company","Comparative law","Competition (economics)","Competition law","Complaint","Composition of matter","Confidence","Confidentiality","Conflict (process)","Consent","Consequential damages","Consultant","Consumer protection","Contract","Contract law","Contractual term","Contravention","Conveyancing","Copyright","Copyright infringement","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporation","Corporations","Cost","Courier","Court","Covenant (law)","Creditor","Creditors' rights","Culture","Currency","Custom","Customer","Customs","Damages","Data","Debt","Debtor","Decree","Deed","Deed of trust (real estate)","Disclaimer","Discounts and allowances","Discovery (law)","Doctrines","Documents","Dollar","Domain name","Dosage form","Dose (biochemistry)","Drug Master File","Drug development","Drug discovery","Drug policy","Drug safety","Drugs","Earthquake","Economic sectors","Economics","Economics of regulation","Economy","Efficacy","Emergence","Employment","Enantiomer","English language","Environmental law","Epistemology","Equity (finance)","Equity (law)","Error","Ethical principles","Ethically disputed business practices","Ethics","Ethics committee","European Medicines Agency","European Union","Evidence","Exchange rate","Excise","Excretion","Exercise","Existence","Expense","Experience","Expert","Expert witness","Explosion","Failure","Fair market value","Fax","Federal Food, Drug, and Cosmetic Act","Federal Trade Commission","Federal government of the United States","Federal judiciary of the United States","Fee","Finance","Financial economics","Financial markets","Financial services","Flood","Food","Food and Drug Administration","Forbearance","Force majeure","Formula","Fraudulent conveyance","General counsel","Generally Accepted Accounting Principles (United States)","Goal","God","Good manufacturing practice","Goods","Government","Government agencies","Government agency","Government and personhood","Government information","Government institutions","Government-related organizations","Grace period","Gross negligence","Hart–Scott–Rodino Antitrust Improvements Act","Haryana","Health","Health care","Health economics","Health policy","Health research","Health sciences","Healthcare industry","Healthcare management","Healthcare quality","Herd","Homology (biology)","Human activities","Human communication","Human rights","Hypercholesterolemia","Hyperlipidemia","Hypertriglyceridemia","Imperfect competition","In vitro","In vivo","Income","Indemnity","Indenture","Independent contractor","India","Industries","Industry","Information","Information science","Ingredient","Injunction","Inquiry","Insolvency","Insurance","Intangible assets","Intellectual property","Intellectual property law","Intellectual works","Interest","International law","Invention","Inventor (patent)","Investigational New Drug","Investment","Investment banking","Investor","Invoice","Invoice price","Isomer","Jargon","Judgment (law)","Judiciaries","Jurisdiction","Jurisprudence","Justice","Justification","Know-how","Knowledge","Law","Law and economics","Law of obligations","Law of the United States","Lawsuit","Lawyer","Leadership","Lease","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal liability","Legal literature","Legal procedure","Legal remedy","Legal writing","Letters patent","Liability (financial accounting)","Liability insurance","License","Life sciences","Life sciences industry","Liquidation","Machine","Mail","Maintenance fee (patent)","Major trauma","Managed care","Management","Manufacturing","Market (economics)","Market value","Marketing","Marketing Authorization Application","Marketplace","Matter","Mediation","Medical humanities","Medical research","Medical specialties","Medical treatments","Medication","Medication package insert","Medicinal chemistry","Medicine","Mergers and acquisitions","Metabolism","Metaphysics","Microeconomics","Milestone","Misappropriation","Misconduct","Money","Monopoly (economics)","Morality","Mortgage law","National agencies for drug regulation","Natural resources law","Negligence","New Drug Application","New York (state)","New York City","Non-disclosure agreement","North Carolina","Nothing","Open government","Opinion","Option (finance)","Organization","Ownership","Packaging and labeling","Paragraph","Patent","Patent application","Patent infringement","Patent law","Patent prosecution","Patentability","Patient","Patient safety","Payment","Payments","Percentage","Personal finance","Personality traits","Pharmaceutical Product Development","Pharmaceutical formulation","Pharmaceutical industry","Pharmaceutical sciences","Pharmaceuticals policy","Pharmaceutics","Pharmacokinetics","Pharmacology","Pharmacy","Phases of clinical research","Philosophy","Physical sciences","Placebo","Political economy","Political science","Politics","Postmarketing surveillance","Practice of law","Pre-clinical development","Press release","Prevention","Preventive healthcare","Price","Pricing","Principles","Privacy","Private law","Prodrug","Product","Product liability","Product recall","Production and manufacturing","Products of chemical industry","Professional ethics","Prohibition","Property","Property law","Prosecutor","Provisional application","Psychological concepts","Psychology","Public administration","Public health","Public law","Public policy","Public records","Public sector","Public sphere","Public utility","Quality","Quality control","Ranbaxy Laboratories","Reason","Rebate (marketing)","Receipt","Registered mail","Regulation","Regulatory agency","Regulatory compliance","Reimbursement","Research","Research and development","Right to property","Rights","Royalty payment","Rule of law","Rules","Safety","Sales","Salt","Science","Section 301 of the Trade Act of 1974","Section 504 of the Rehabilitation Act","Security","Security (finance)","Separation of powers","Service industries","Service mark","Services (economics)","Signature","Social information processing","Social institutions","Social issues","Sociological theories","Sources","Specification (technical standard)","Statin","Strict liability","Strike action","Supply chain management","Supranational union","Surveillance","Tablet computer","Tax","Tax deduction","Technology","Telephone","The Wall Street Journal","Theories of law","Therapy","Third-party beneficiary","Tort","Tort law","Toxicology","Trade","Trade dress","Trade name","Trade secret","Trademark","Transport","Trial","Trust law","Trustee","U.S. Securities and Exchange Commission","United States","United States Department of Justice","United States Patent and Trademark Office","United States dollar","Urban, rural, and regional economics","Value (ethics)","Videotelephony","Virtue","Waiver","Wall Street","War","Warranty","Wilmington, North Carolina","Wire","Wire transfer","Withholding tax","Witness","World Intellectual Property Organization","Written communication","Wrongful death claim"],"person_names":["pii      rbx","rbx","sales milestones","v."],"vars":{"Party":{"PHARMACO INVESTMENTS, INC.":"[[Party 1]]","RANBAXY LABORATORIES LTD.":"[[Party 3]]","a wholly owned subsidiary of Pharmaceutical Product Development, Inc., a North Carolina corporation having its principal place of business at 3151 South 17th Street, Wilmington":"[[Party 2]]"}},"organization_names":["alliance manager","certified public accountant","ctm","development","development and regulatory approval","development plan","inc.","investigational new drug application","irb","licensed products","maa","major regulatory filings","milestone payments","pharmaceutical product development","pii","ppd","ppd guarantee","ranbaxy","rbx intellectual property","rbx patent","rbx patents","regulatory approval","residual obligation","studies","united states food"],"agreement_id":"aad7a2e31a0e369a1ea67d6ab841877a70af22c28e7237cf522e3d1c103cdfa7","terms":["**      [*","** (expressly excluding any requirement to complete any **","** (other than **","** (“Major Regulatory Filings”) for a Licensed Product for the Indication as promptly as practicable. In executing the Development Plan, PII shall be solely responsible for all costs and expenses relating to the Development Plan and obtaining Regulatory Approval for the Licensed Product(s). Without limiting the generality of the foregoing, PII shall be responsible for the preparation, filing and prosecution of all agency applications for obtaining Regulatory Approvals in the Territory which are required to commercially sell or use the Licensed Product(s) in the Territory and for all subsequent related submissions. All Regulatory Documentation and Regulatory Approvals in the Territory shall be owned and filed in the name of PII. PII shall use Diligent Efforts in preparing the Major Regulatory Filings for Regulatory Approval of the Licensed Product(s) and in causing such agency applications to progress through the Regulatory Approval process. PII shall use Diligent Efforts for the preparation and submission of all governmental and agency applications for Regulatory Approval for a Licensed Product for the Indication in countries of the Territory other than **","** are performed using different comparitors and/or patient populations, the Milestone Payment under this Section 5.02(a) shall be triggered upon the Completion of the last arm of such **","** are performed using different comparitors and/or patient populations, the Milestone Payment under this Section 5.02(b) shall be triggered upon the Completion of **","** identified as **","** indication. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, in the event PII pursues the Development of the Compound (whether in a single or combination product) for the treatment of **","** other than the Compound and the Licensed Product(s) hereunder, or **","** percent (**","** relating to such **","** shall occur upon the Completion of the **","**% to the Party controlling the enforcement action and **","**) relating to such **","*****","***] Confidential treatment requested; certain information omitted and filed separately with the SEC. contemplated in the Development Plan, then Completion of the **","**, provided that (i) such services are limited to those that are usual and customary for clinical research organizations in general, and PII and its Affiliates in particular; and (ii) PII and its Affiliates shall not retain (1) any right, title, interest or license in any such **","**,**","**. At the time RBX decides to exercise its co-marketing rights, RBX may send to PII a written request to discuss the possibility of RBX **","**. For clarity, if **","**. In the event multiple arms of a **","**.**","**Amendment.**","**Arbitration.**","**Assignability.**","**Audit.**","**Authorized Disclosure.**","**Books and Records.**","**Clinical Milestone Payments.**","**Counterparts.**","**DEVELOPMENT PLAN**","**Date**","**Development Reports.**","**Development; Regulatory Activities and Approvals.**","**Dollars.**","**Early Termination by PII**","**Employee Agreements.**","**Entire Agreement.**","**Exclusivity**","**Exercise of Option.**","**Force Majeure.**","**Foreign Payments.**","**General Principle**","**Governing Law.**","**Headings.**","**Indemnification.**","**Infringement of Patent Rights.**","**Jointly Prepared.**","**Launch and Marketing.**","**License Fee.**","**License Option.**","**License Terms**","**License to RBX Intellectual Property**","**Limitations on Publications.**","**Manufacturing**","**Material Breach.**","**Method of Calculation.**","**Milestone**","**No Third Party Beneficiary**","**Nondisclosure of Confidential Information.**","**Notices.**","**Notification.**","**OPTION AND LICENSE AGREEMENT**","**Option Covenants.**","**Ownership of PII Information.**","**Ownership of Patents.**","**PPD Guarantee.**","**Patent Marking.**","**Patent Prosecution.**","**Payments to Third Parties.**","**Product Recalls and Insurance**","**RBX Co-Marketing Rights.**","**RBX Know-How**","**RBX PATENTS**","**Relationship of the Parties.**","**Release of Information.**","**Remaining Licensed Product.**","**Residual Obligation upon Termination.**","**Right to Sublicense.**","**Rights of RBX Upon Early Termination.**","**Royalties.**","**Royalty Period.**","**SCHEDULE 1.13**","**SCHEDULE 1.53**","**SCHEDULE 4.05**","**Sales Milestone Event**","**Sales Milestone Payment**","**Sales Milestones.**","**Schedule 1.13**","**Schedule 1.53**","**Schedule 4.05**","**Schedules.**","**Severability.**","**Term of the Option.**","**Term.**","**Termination for Failure to Meet Key Development Milestones**","**Termination for Insolvency/Bankruptcy.**","**Third Party Infringement Actions.**","**Trademarks.**","**Transfer of Know-How.**","**Voluntary Termination by PII.**","**WITNESSETH THAT:**","**Waiver.**","**Warranties by PII.**","**Warranties by RBX.**","**[*","**“Development”**","**“GAAP”**","**“Joint Invention”**","**“Joint Patents”**","*]      [*","*] dollars ($[*","*] per occurrence (or claim) and an annual aggregate of **","*] that are in RBX’s possession as of the Effective Date (“RBX [*","*] totaling approximately [*","*]**","*]. PII will notify RBX in writing upon Completion of the **","*]. PII will notify RBX in writing upon the Completion of the **","*except*","“**Force Majeure”**","“**Option Period**”","“**Option Termination Date**”","“**Option**”","“AAA”","“Agreement”","“Alliance Manager”","“Claim”","“DMF”","“Defaulting Party”","“Effective Date”","“Indemnifying Party”","“Joint Invention”","“Joint Patent Rights”","“Joint Patents”","“License Fee”","“Major Regulatory Filings”","“Milestone Payment” and collectively the “Milestone Payments”","“Non-Defaulting Party”","“Option Period”","“Option”","“PII Patents”","“PII”","“PPD”","“Paragraph IV Challenge” and collectively with an Infringement Action, “Section 8.03 Actions”","“RBX [*]”","“RBX”","“Researcher”","“alleged infringement”"]}}